Evidence map›Paper›PMID 38797909›Full record

ReviewCurrent protein & peptide science2024

Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.

Katarzyna Grabowska, Michalina Grzelak, Lin-Yong Zhao, Elżbieta Płuciennik, Zbigniew Pasieka, Mateusz Kciuk, Adrianna Gielecińska, Aleksander K Smakosz, Żaneta Kałuzińska-Kołat, Damian Kołat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katarzyna GrabowskaDepartment of Functional Genomics, Medical University of Lodz, Żeligowskiego 7/9, 90-752, Lodz, Poland.ORCID 0009-0001-4798-0304
Michalina GrzelakDepartment of Functional Genomics, Medical University of Lodz, Żeligowskiego 7/9, 90-752, Lodz, Poland.ORCID 0009-0002-6766-0612
Lin-Yong ZhaoDepartment of General Surgery & Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-0884-4657
Elżbieta PłuciennikDepartment of Functional Genomics, Medical University of Lodz, Żeligowskiego 7/9, 90-752, Lodz, Poland.ORCID 0000-0002-6682-0402
Zbigniew PasiekaDepartment of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136, Lodz, Poland.ORCID 0000-0001-8931-0213
Mateusz KciukDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237, Lodz, Poland.ORCID 0000-0002-8616-3825
Adrianna GielecińskaDepartment of Molecular Biotechnology and Genetics, University of Lodz, Banacha 12/16, 90-237, Lodz, Poland.ORCID 0000-0001-9562-3582
Aleksander K SmakoszDepartment of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, 50-367, Wroclaw, Poland.ORCID 0000-0001-8458-6413
Żaneta Kałuzińska-KołatDepartment of Functional Genomics, Medical University of Lodz, Żeligowskiego 7/9, 90-752, Lodz, Poland.ORCID 0000-0002-2335-3293
Damian KołatDepartment of Functional Genomics, Medical University of Lodz, Żeligowskiego 7/9, 90-752, Lodz, Poland.ORCID 0000-0002-1086-3796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia is a plasma bleeding disorder characterized by a deficiency of certain blood clotting factors. The most common forms of this disease, i.e., type A and type B, affect approximately 400,000 people worldwide. Without appropriate treatment ensuring the proper coagulation cascade, this disease may lead to serious disability. Minimizing patient discomfort is possible via replacement therapy, consisting of the substitution of a missing coagulation factor

Indexed as

Antibodies, BispecificAntibodies, Monoclonal, HumanizedClinical Trials as TopicHemophilia AFactor VIIIHemorrhageHumansAntibodies, BispecificAntibodies, Monoclonal, HumanizedemicizumabFactor VIIIclinical trials.Emicizumabhemophilia Amonoclonal antibodypatientstherapy

Identifiers

PMID38797909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.